Company / SG&A Expense
GoodRx Holdings, Inc. SG&A Expense History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$114.0M
FY2025
5-year range
$114.0M / $154.7M
FY2021-FY2025
Trend
-3.3%
vs FY2024
Sector context
#210 of 307
Information Technology
What the data says
At $114M, GoodRx Holdings, Inc.'s sg&a expense ranks #98 of 307 in the Information Technology sector. SG&A Expense has declined for 5 consecutive years, from $461M in FY2020 to $114M in FY2025.
Based on SEC 10-K filings.
$114M in FY2025 with a 5-year CAGR of -24.4%.
Improved from $126M to $114M over the past 2 years.
Information Technology sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- -7.7%
- 5-Year CAGR
- -24.4%
- 10-Year CAGR
- -
Sector benchmark
#98 of 307 in Information TechnologyTop 32% of 307This company $114.0M Sector average $695.9M
▼
-83.6% below sector average
Key checks
Key Insights
- GoodRx Holdings, Inc.'s sg&a expense has declined for 5 consecutive years.
- 5-year CAGR of -24.4%, indicating a declining trend.
- In FY2025, sg&a expense decreased 3.3% year-over-year.
- Ranks #210 out of 307 companies in the Information Technology sector.
Company context
Key Data Points
- Altman Z-Score 0.44 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $114.0M | -3.3% |
| FY2024 | $117.9M | -6.1% |
| FY2023 | $125.5M | -13.3% |
| FY2022 | $144.8M | -6.4% |
| FY2021 | $154.7M | -66.5% |
| FY2020 | $461.5M | +3040.8% |
| FY2019 | $14.7M | +75.8% |
| FY2018 | $8.4M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026